ArticleiGIE : innovation, investigation and insights2025
Endoscopic ultrasound-guided fine-needle biopsy as a novel approach for risk stratification of pancreatic cystic lesions.
Article in iGIE : innovation, investigation and insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Minimally Invasive Sampling Techniques for Pancreatic and Pulmonary Nodules: A Review of the Evolution of Guidance and Sampling Methods.Diagnostic cytopathology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Unlike fine-needle biopsy (FNB), fine-needle aspiration (FNA) is limited by its inability to preserve histopathology. We compared the diagnostic yield of endoscopic ultrasound (EUS)-guided FNA and EUS-FNB for pancreatic cystic lesions (PCLs), hypothesizing that EUS-FNB would frequently provide a tissue diagnosis. Methods: A single-center retrospective cohort study was conducted from 2022 to 2023 on patients with PCLs who underwent either EUS-FNA or EUS-FNB. We compared cyst characteristics and pathology reports to assess diagnostic yield. The relative risk (RR) was calculated to compare FNB's probability of identifying intraductal papillary mucinous neoplasm (IPMN) grade compared with FNA. Results: A total of 130 PCLs were identified (FNA: n = 34; FNB: n = 96). Patients had a mean age of 68 ± 12 years, and 49% were women. Sex, age, cyst size, location, and presence of pancreatic ductal dilation did not differ significantly between FNA and FNB groups. FNB showed a significantly higher diagnostic yield compared with FNA (81% vs 62%; Conclusions: Our results reflect one of the first studies, to our knowledge, to consider the diagnostic role of FNB in evaluating PCLs. These preliminary results suggest that FNB may have a potential for high diagnostic performance in PCLs and warrant further exploration using a larger cohort and randomized controlled trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.